China · Delayed Price · Currency is CNY Hualan Biological Vaccine Statistics
Total Valuation
SHE:301207 has a market cap or net worth of CNY 9.81 billion. The enterprise value is 7.06 billion.
| Market Cap | 9.81B |
| Enterprise Value | 7.06B |
Important Dates
The next estimated earnings date is Wednesday, August 26, 2026.
| Earnings Date | Aug 26, 2026 |
| Ex-Dividend Date | Jun 15, 2026 |
Share Statistics
SHE:301207 has 595.00 million shares outstanding. The number of shares has decreased by -0.29% in one year.
| Current Share Class | 595.00M |
| Shares Outstanding | 595.00M |
| Shares Change (YoY) | -0.29% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 0.26% |
| Owned by Institutions (%) | 3.03% |
| Float | 93.43M |
Valuation Ratios
The trailing PE ratio is 52.30 and the forward PE ratio is 45.78.
| PE Ratio | 52.30 |
| Forward PE | 45.78 |
| PS Ratio | 8.14 |
| PB Ratio | 1.71 |
| P/TBV Ratio | 1.71 |
| P/FCF Ratio | 21.74 |
| P/OCF Ratio | 21.28 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 29.26, with an EV/FCF ratio of 15.64.
| EV / Earnings | 37.63 |
| EV / Sales | 5.86 |
| EV / EBITDA | 29.26 |
| EV / EBIT | 70.63 |
| EV / FCF | 15.64 |
Financial Position
The company has a current ratio of 4.15
| Current Ratio | 4.15 |
| Quick Ratio | 3.66 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 81.01 |
Financial Efficiency
Return on equity (ROE) is 3.18% and return on invested capital (ROIC) is 3.29%.
| Return on Equity (ROE) | 3.18% |
| Return on Assets (ROA) | 0.87% |
| Return on Invested Capital (ROIC) | 3.29% |
| Return on Capital Employed (ROCE) | 1.73% |
| Weighted Average Cost of Capital (WACC) | 7.67% |
| Revenue Per Employee | 1.70M |
| Profits Per Employee | 264,842 |
| Employee Count | 708 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.14 |
Taxes
In the past 12 months, SHE:301207 has paid 5.41 million in taxes.
| Income Tax | 5.41M |
| Effective Tax Rate | 2.80% |
Stock Price Statistics
The stock price has decreased by -0.42% in the last 52 weeks. The beta is 0.62, so SHE:301207's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | -0.42% |
| 50-Day Moving Average | 18.98 |
| 200-Day Moving Average | 19.83 |
| Relative Strength Index (RSI) | 37.36 |
| Average Volume (20 Days) | 4,467,623 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SHE:301207 had revenue of CNY 1.20 billion and earned 187.51 million in profits. Earnings per share was 0.32.
| Revenue | 1.20B |
| Gross Profit | 875.46M |
| Operating Income | 99.91M |
| Pretax Income | 192.92M |
| Net Income | 187.51M |
| EBITDA | 241.17M |
| EBIT | 99.91M |
| Earnings Per Share (EPS) | 0.32 |
Balance Sheet
The company has 2.75 billion in cash and n/a in debt, with a net cash position of 2.75 billion or 4.62 per share.
| Cash & Cash Equivalents | 2.75B |
| Total Debt | n/a |
| Net Cash | 2.75B |
| Net Cash Per Share | 4.62 |
| Equity (Book Value) | 5.74B |
| Book Value Per Share | 9.65 |
| Working Capital | 3.38B |
Cash Flow
In the last 12 months, operating cash flow was 460.78 million and capital expenditures -9.65 million, giving a free cash flow of 451.14 million.
| Operating Cash Flow | 460.78M |
| Capital Expenditures | -9.65M |
| Depreciation & Amortization | 141.26M |
| Net Borrowing | -300.00M |
| Free Cash Flow | 451.14M |
| FCF Per Share | 0.76 |
Margins
Gross margin is 72.65%, with operating and profit margins of 8.29% and 15.56%.
| Gross Margin | 72.65% |
| Operating Margin | 8.29% |
| Pretax Margin | 16.01% |
| Profit Margin | 15.56% |
| EBITDA Margin | 20.01% |
| EBIT Margin | 8.29% |
| FCF Margin | 37.44% |
Dividends & Yields
This stock pays an annual dividend of 1.60, which amounts to a dividend yield of 9.71%.
| Dividend Per Share | 1.60 |
| Dividend Yield | 9.71% |
| Dividend Growth (YoY) | 600.00% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 254.51% |
| Buyback Yield | 0.29% |
| Shareholder Yield | 10.00% |
| Earnings Yield | 1.91% |
| FCF Yield | 4.60% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for SHE:301207 is 26.84, which is 62.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 26.84 |
| Price Target Difference | 62.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 14.18% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 7, 2023. It was a forward split with a ratio of 1.5.
| Last Split Date | Jun 7, 2023 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
SHE:301207 has an Altman Z-Score of 7.44 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.44 |
| Piotroski F-Score | 6 |